Answers are grounded in this paper and cite their sources.
The human anti-cancer drug Cytosine arabinoside (ana-C) was encapsulated in canine erythrocytes. When these autologous carrier cells were injected into dogs, the drug was slowly released into plasma. Erythrocyte encapsulation increased the plasma half-life of ara-C in dogs about 50-fold over that of the injected free drug. The whole blood half-life of encapsulated drug was 4.6 days and the elimination constant was 0.150 day-1. Erythrocyte encapsulation holds promise as a drug-delivering technique for treatment of some human and animal diseases, particularly with drugs that are highly toxic or have normally short biological half-life. It also could be used to sustain given concentrations of drugs.
No takes yet. Share an insight, caveat, or question.
DeLoach et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: